Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer with N2 Disease

Shilpen Patel, Rachel E. Sanborn, Charles Thomas

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Non-small cell lung cancer remains the leading cause of cancer death in men and women, with a significant proportion of patients having locally advanced, unresectable disease at the time of diagnosis. Although significant advances in definitive therapy have been made with the concurrent administration of combination cytotoxic chemotherapy and thoracic irradiation, recurrence rates are still high, and long-term survival rates are suboptimal. The application of more modern radiation techniques and the addition of molecularly targeted systemic agents may add further benefit in survival.

Original languageEnglish (US)
Pages (from-to)393-401
Number of pages9
JournalThoracic Surgery Clinics
Volume18
Issue number4
DOIs
StatePublished - Nov 2008

Fingerprint

Chemoradiotherapy
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Cause of Death
Thorax
Survival Rate
Radiation
Recurrence
Survival
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer with N2 Disease. / Patel, Shilpen; Sanborn, Rachel E.; Thomas, Charles.

In: Thoracic Surgery Clinics, Vol. 18, No. 4, 11.2008, p. 393-401.

Research output: Contribution to journalArticle

Patel, Shilpen ; Sanborn, Rachel E. ; Thomas, Charles. / Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer with N2 Disease. In: Thoracic Surgery Clinics. 2008 ; Vol. 18, No. 4. pp. 393-401.
@article{6fab7a00aa1842aa9536f65b8819367e,
title = "Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer with N2 Disease",
abstract = "Non-small cell lung cancer remains the leading cause of cancer death in men and women, with a significant proportion of patients having locally advanced, unresectable disease at the time of diagnosis. Although significant advances in definitive therapy have been made with the concurrent administration of combination cytotoxic chemotherapy and thoracic irradiation, recurrence rates are still high, and long-term survival rates are suboptimal. The application of more modern radiation techniques and the addition of molecularly targeted systemic agents may add further benefit in survival.",
author = "Shilpen Patel and Sanborn, {Rachel E.} and Charles Thomas",
year = "2008",
month = "11",
doi = "10.1016/j.thorsurg.2008.07.003",
language = "English (US)",
volume = "18",
pages = "393--401",
journal = "Thoracic Surgery Clinics",
issn = "1547-4127",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer with N2 Disease

AU - Patel, Shilpen

AU - Sanborn, Rachel E.

AU - Thomas, Charles

PY - 2008/11

Y1 - 2008/11

N2 - Non-small cell lung cancer remains the leading cause of cancer death in men and women, with a significant proportion of patients having locally advanced, unresectable disease at the time of diagnosis. Although significant advances in definitive therapy have been made with the concurrent administration of combination cytotoxic chemotherapy and thoracic irradiation, recurrence rates are still high, and long-term survival rates are suboptimal. The application of more modern radiation techniques and the addition of molecularly targeted systemic agents may add further benefit in survival.

AB - Non-small cell lung cancer remains the leading cause of cancer death in men and women, with a significant proportion of patients having locally advanced, unresectable disease at the time of diagnosis. Although significant advances in definitive therapy have been made with the concurrent administration of combination cytotoxic chemotherapy and thoracic irradiation, recurrence rates are still high, and long-term survival rates are suboptimal. The application of more modern radiation techniques and the addition of molecularly targeted systemic agents may add further benefit in survival.

UR - http://www.scopus.com/inward/record.url?scp=53649094623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649094623&partnerID=8YFLogxK

U2 - 10.1016/j.thorsurg.2008.07.003

DO - 10.1016/j.thorsurg.2008.07.003

M3 - Article

C2 - 19086608

AN - SCOPUS:53649094623

VL - 18

SP - 393

EP - 401

JO - Thoracic Surgery Clinics

JF - Thoracic Surgery Clinics

SN - 1547-4127

IS - 4

ER -